JP2023515665A - 神経伝達物質トランスポーターの阻害剤の有効性を評価するための組成物及び方法 - Google Patents

神経伝達物質トランスポーターの阻害剤の有効性を評価するための組成物及び方法 Download PDF

Info

Publication number
JP2023515665A
JP2023515665A JP2022552541A JP2022552541A JP2023515665A JP 2023515665 A JP2023515665 A JP 2023515665A JP 2022552541 A JP2022552541 A JP 2022552541A JP 2022552541 A JP2022552541 A JP 2022552541A JP 2023515665 A JP2023515665 A JP 2023515665A
Authority
JP
Japan
Prior art keywords
snp
transporter
norepinephrine
treatment
serotonin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022552541A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023515665A5 (https=
Inventor
ウィテカー，ジョン，ダブリュー．
ダリ，ザフリン
サン，ホン
ルー，ハイピン
リー，シャオジュン
ウー，ウィルソン
ルオ，ウェン
Original Assignee
デノボ バイオファーマ エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デノボ バイオファーマ エルエルシー filed Critical デノボ バイオファーマ エルエルシー
Publication of JP2023515665A publication Critical patent/JP2023515665A/ja
Publication of JP2023515665A5 publication Critical patent/JP2023515665A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2022552541A 2020-03-06 2021-02-23 神経伝達物質トランスポーターの阻害剤の有効性を評価するための組成物及び方法 Pending JP2023515665A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062986603P 2020-03-06 2020-03-06
US62/986,603 2020-03-06
PCT/US2021/019265 WO2021178166A1 (en) 2020-03-06 2021-02-23 Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters

Publications (2)

Publication Number Publication Date
JP2023515665A true JP2023515665A (ja) 2023-04-13
JP2023515665A5 JP2023515665A5 (https=) 2024-03-05

Family

ID=77613738

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022552541A Pending JP2023515665A (ja) 2020-03-06 2021-02-23 神経伝達物質トランスポーターの阻害剤の有効性を評価するための組成物及び方法

Country Status (13)

Country Link
US (1) US12612661B2 (https=)
EP (1) EP4106872A4 (https=)
JP (1) JP2023515665A (https=)
KR (1) KR20230005816A (https=)
CN (1) CN115515680A (https=)
AR (1) AR121515A1 (https=)
AU (1) AU2021231683A1 (https=)
BR (1) BR112022017770A2 (https=)
CA (1) CA3174572A1 (https=)
IL (1) IL296168A (https=)
MX (1) MX2022010816A (https=)
TW (1) TW202146660A (https=)
WO (1) WO2021178166A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000019303A1 (it) * 2020-08-05 2022-02-05 Univ Degli Studi Di Brescia Analoghi strutturali del metilfenidato come agenti disease-modifying della malattia di parkinson
CN114848835B (zh) * 2022-03-22 2023-08-25 暨南大学 塞来昔布的聚乙二醇修饰及连接叶酸基团的靶向药物分子及制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6945457B1 (en) * 1996-05-10 2005-09-20 Transaction Holdings Ltd. L.L.C. Automated transaction machine
JP4198582B2 (ja) * 2003-12-02 2008-12-17 独立行政法人科学技術振興機構 タンタルオキシナイトライド酸素還元電極触媒
WO2007128884A1 (en) * 2006-05-09 2007-11-15 Oy Jurilab Ltd Novel genes and markers in type 2 diabetes and obesity
US20080299125A1 (en) 2006-06-05 2008-12-04 Perlegen Sciences, Inc. Genetic basis of treatment response in depression patients
WO2008065544A2 (en) 2006-09-11 2008-06-05 Mcgill University Genetic predictors of risk for type 2 diabetes mellitus
EP2243834A1 (en) 2007-03-05 2010-10-27 Cancer Care Ontario Assessment of risk for colorectal cancer
US20170029892A1 (en) 2009-05-29 2017-02-02 Jay L. Lombard Methods and compositions for the treatment of post-traumatic stress disorder
US8355927B2 (en) * 2010-11-05 2013-01-15 Genomind, Llc Neuropsychiatric test reports
EP2707498B1 (en) 2011-01-31 2018-01-17 Denovo Biomarkers Inc. Method for discovering pharmacogenomic biomarkers
WO2012156515A1 (en) * 2011-05-18 2012-11-22 Rheinische Friedrich-Wilhelms-Universität Bonn Molecular analysis of acute myeloid leukemia
CA2838207A1 (en) 2011-06-08 2012-12-13 Denovo Biopharma (Hangzhou) Ltd. Co. Methods and compositions of predicting activity of retinoid x receptor modulator
US20140274764A1 (en) 2013-03-15 2014-09-18 Pathway Genomics Corporation Method and system to predict response to treatments for mental disorders
US20170253928A1 (en) 2013-03-15 2017-09-07 Pathway Genomics Corporation Method and system to predict response to treatments for mental disorders
TR201907106T4 (tr) 2014-03-14 2019-06-21 Caredx Inc Bir transplant alıcısında immünosüpresif terapileri izleme yöntemleri.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PSYCHONEUROENDOCRINOLOGY, vol. 38, no. 10, JPN7025001649, 2013, pages 2249 - 2257, ISSN: 0005750894 *

Also Published As

Publication number Publication date
US12612661B2 (en) 2026-04-28
CN115515680A (zh) 2022-12-23
WO2021178166A1 (en) 2021-09-10
CA3174572A1 (en) 2021-09-10
US20230193388A1 (en) 2023-06-22
MX2022010816A (es) 2022-12-13
BR112022017770A2 (pt) 2022-11-29
TW202146660A (zh) 2021-12-16
EP4106872A4 (en) 2024-04-10
EP4106872A1 (en) 2022-12-28
KR20230005816A (ko) 2023-01-10
IL296168A (en) 2022-11-01
AU2021231683A1 (en) 2022-09-22
AR121515A1 (es) 2022-06-08

Similar Documents

Publication Publication Date Title
US20210108266A1 (en) Method for discovering pharmacogenomic biomarkers
US20230074781A1 (en) Methods and composition for the prediction of the activity of enzastaurin
US12612661B2 (en) Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters
JP2010515467A (ja) 心筋梗塞及び心不全における診断マーカー及び薬剤設計のためのプラットホーム
HK40083504A (en) Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters
WO2023097197A2 (en) Compositions and methods for assessing the efficacy of polynucleotide delivery and cancer therapy
HK1196399A (en) Method for discovering pharmacogenomic biomarkers
HK1196399B (en) Method for discovering pharmacogenomic biomarkers
HK40011257A (en) Methods and composition for the prediction of the activity of enzastaurin
HK40011257B (en) Methods and composition for the prediction of the activity of enzastaurin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250416

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250715

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251016

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260410